Bone marrow oedema syndrome of the foot and ankle in a paediatric population: a retrospective case series with serial MRI evaluation

Hannah De Houwer¹
Nathalie Van Beek¹
Sandra Prinsen²
Anne Van Riet¹
Jeoffrey De Roeck³
Stefaan Verfaillie¹

Abstract

Purpose By means of a case series we wanted to describe and correlate the clinical and imaging features of bone marrow oedema syndrome (BMOS) of the foot and ankle in children.

Methods A retrospective data study was performed on patients born on or after 01 January 2001 who underwent multiple MRI scans of the foot and ankle for pain symptoms. Six patients who presented with increased signal intensity on T2-weighted MR imaging without any underlying causes or concomitant pathology were included.

Results All patients, three boys and three girls with a mean age of 11 years (8 to 14), displayed patchy areas of increased signal intensity on T2-weighted and turbo inversion recovery magnitude (TIRM) images. On average, six tarsal bones were involved (4 to 8). In all patients, treatment consisted of rest and/or protected weight-bearing. The mean time for symptoms to improve during treatment was 6 months (1 to 16). The mean duration of treatment was nine months (3 to 16). In all patients clinical and imaging symptoms were strongly correlated and regressed in time.

Conclusion BMOS as a pathological entity should be considered in paediatric patients with foot and ankle pain without a clear underlying cause, and characteristic T2-weighted and TIRM signal intensity increase on MRI images. As BMOS is transient and self-limiting, conservative treatment is advised while the oedema regresses. An early diagnosis of this pathology could prevent unnecessary diagnostic investigations and invasive treatments.

Level of Evidence: IV

Cite this article: De Houwer H, Van Beek N, Prinsen S, Van Riet A, De Roeck J, Verfaillie S. Bone marrow oedema syndrome of the foot and ankle in a paediatric population: a retrospective case series with serial MRI evaluation. J Child Orthop 2020;14:440-450. DOI: 10.1302/1863-2548.14.190189

Keywords: bone marrow oedema; pain; foot and ankle; paediatric; child; case series

Introduction

Bone marrow oedema syndrome (BMOS) refers to a group of conditions characterized by extremity pain and increased interstitial fluid within the bone marrow, with unknown cause.¹-⁴ First used as a general term in knee pathology by Hofmann et al in 2004,¹ it has been described as acute bone marrow oedema, bone marrow lesions, (migratory) transient osteoporosis, regional migratory osteoporosis and transient bone marrow oedema (TBMO).⁵ It is a relatively rare condition, not often described for the upper limb or in the paediatric population,⁶ mostly affecting the hip and knee in middle aged men and younger women.³,⁶ Because foot and ankle involvement in BMOS is quite uncommon, and has rather unspecific symptoms, there is often a delay in diagnosis, which leads to an extended period of pain and impaired functionality in daily life.¹-³,⁷-⁹ BMOS is characterized by a self-limiting course as the symptoms usually disappear within three to 12 months.¹⁰,¹¹ Treatment of BMOS focusses on pain relief and shortening of symptom duration if possible.¹,³ Symptomatic treatments can consist of non- or partial weight-bearing by means of a cast or walker boot, nonsteroidal anti-inflammatory drugs, calcium, calcitonin, physio-, relaxation and massage therapy.²,³,¹²-¹⁶ Pharmacological treatments include iloprost, a synthetic prostacyclin analogue⁹,¹¹,¹⁷-²³ bisphosphonates and vitamin D.²,⁷,²⁴-²⁸ Surgical treatment consisting of core decompression or drilling have mostly been described in the proximal femur.²²,²⁹

Only a few case reports have been published concerning BMOS in the paediatric population.¹⁶,³⁰-³³ In imaging studies, which are focused on tarsal bone marrow in
children, high-signal T2-weighted changes of the bone marrow on MRI are mostly considered to be a normal, physiological finding representing residual hematopoietic marrow instead of a pathologic entity. A limitation of many of these studies is the lack of clinical data and thus the absence of a correlation between MRI findings and the clinical evaluation.

In this study we would like to re-evaluate the underdiagnosed concept of BMOS in the foot and ankle in a pediatric population. By means of a case series we observe the correlation between clinical symptoms and MRI imaging features.

**Materials and methods**

A retrospective database search was conducted using image viewing software (CARESTREAM Vue PACS, Carestream Health Inc., Rochester, New York, USA), querying MRI scans of the foot and ankle in a population born on or after 1 January 2001. Only patient cases of children who had multiple MRI scans were included (21 cases in total). Images and protocols were scrutinized by the first author (HDH). In total, 12 cases were selected for this study based on MRI susceptibility for BMOS. We excluded fractures, osteochondral lesions, tarsal coalitions, tendon pathology, inflammatory and infectious disease and malignancies, as these diagnoses could generate a secondary bone marrow oedema image. Patients with imaging but no clinical data records were also excluded. The following data was recorded from patient files: sex, date of birth, medical history, affected side, history of trauma to the affected limb, previous treatments, date of first clinical visit, duration of symptoms before diagnosis, anamnestic symptoms, clinical symptoms, type and duration of treatment, date of amelioration of symptoms, recurrence of symptoms and length of follow-up. These clinical data were reviewed by the first author (HDH), who was not involved in the clinical care of these patients. For the imaging data, the date of the first pathological MRI, the date of improvement of MRI features and localization of the bone marrow oedema were recorded. All images of the selected cases were reviewed by the first author and a specialist musculoskeletal radiologist (JDR). After reviewing the remaining cases, six cases were excluded because

**Table 1 Demographic and clinical features**

| Case | 1 | 2 | 3 | 4 | 5 | 6 |
|------|---|---|---|---|---|---|
| Sex  | Female | Male | Female | Male | Female | Male |
| Age at onset | 9 yrs 8 mths | 8 yrs | 14 yrs 8 mths | 14 yrs 10 mths | 8 yrs 3 mths | 10 yrs 4 mths |
| Medical history | IgA vasculitis, Hashimoto thyroiditis | None | None | None | None | None |
| History of trauma (before first presentation) | Grade 2 ankle sprain | None | None | None | Fall from stairs | Undisplaced fracture |
| Effected side | None | None | None | Right | base proximal phalanx hallux | MT3-4 after step |
| Previous treatments | Weight-bearing cast 4 wks, 6 mths prior | Weight-bearing cast 4 wks | Weight-bearing cast 4 wks | Weight-bearing cast 6 wks | 5 mths prior | on irregular hard |
| Duration of symptoms before diagnosis | 6 mths | 4 mths | 1 yr 3 mths | 1 mth | 5 mths | 5 mths |
| Subjective complaints | Pain on stance, need for crutches or wheelchair | Pain during soccer, quit sports | Pain during running and jumping, quit volleyball | Pain during soccer, quit sports | Unable to bear weight | Pain during gait and sports |
| Clinical examination | No swelling, sinus tarsi palpation | Swelling ankle, sinus tarsi palpation | No swelling, palpation navicular, tibialis anterior tendon | Swelling tibiotalar and subtalar, decreased hindfoot mobility | No swelling, lateral hind- and midfoot palpation | No swelling, sinus tarsi palpation and decreased hindfoot mobility |
| Specific treatment | Soft insoles | Weight-bearing cast 4 wks, insoles | No additional treatment | Weight-bearing soft cast | Soft insoles | No additional treatment |
| Treatment duration | 3 mths | 11 mths | 6 mths | 14 mths | 15 mths | 4 mths |
| Time until improvement of initial symptoms | 4 mths | 1 yr | 6 mths | 2 mths | 6 mths | 5 mths |
| Recurrence/migration | Pain on sporting activities 5 mths after regression of initial symptoms | Migration to TMT1 pain 6 mths after start of treatment | None | Progression of pain at same site after initial improvement, 10 mths after start of treatment | Stagnation of symptoms after 6 mths of initial improvement | None |
| Final regression of symptoms after start of treatment | 16 mths | 1 yr | 6 mths | 14 mths | 16 mths | 5 mths |
| Length of follow-up | 17 mths | 12 mths | 6 mths | 25 mths | 16 mths | 5 mths |
of discrete subchondral fracture lines (three) and merely physiological appearance of the bone marrow oedema pattern (three). MRI scans in our hospital were performed on a 1.5-tesla magnet MRI (Siemens Medical Systems, Erlangen, Germany) and two review scans were executed in another hospital. The standard MRI technique used in our hospital for ankle imaging included coronal, sagittal and axial T1-weighted sequences, axial T2-weighted sequences and sagittal turbo inversion recovery magnitude (TIRM), T2 3D-double-echo steady state with water excitation and T2-weighted sequences. In total six patient cases are discussed in this article.

In addition to the first query, a second query was performed on the same patient population to provide a control group. Patient cases of children with single or multiple MRI scans were selected and imaging protocols were scrutinized. Patient cases with imaging protocols susceptible for BMOS were excluded. In total, ten cases were included in the control group, two cases featuring bilateral MRI imaging. The following data was recorded from patient files: sex, date of birth, date of the MRI, medical history, history of trauma to the affected limb, anamnestic and clinical symptoms, diagnosis and treatment. MRI images of the selected cases were reviewed by the first author (HDH) and a specialist in musculoskeletal radiology (JDR).

Descriptive statistics were performed using Excel (Microsoft Excel 2016, Redmond, Washington, USA). No comparative tests were performed.

**Results**

**Demographics**

Full demographic and clinical data are listed in Table 1. We reviewed three male and three female patients in total. Only one patient (case 1) presented with a medical

Fig. 1 A recurrent disease course was seen in this 14-year-old boy (case 4), as documented by turbo inversion recovery magnitude sagittal MR imaging. Presenting initially with pain in the tibiotalar and subtalar joint and bone marrow oedema appearing to be centred in the talonavicular joint (a); pain gradually improved after three months of protected weight-bearing using a walking boot (b). A new onset of pain was seen ten months after initial presentation, correlating with persistent oedema at the anterior aspect of the talus (c). Symptoms as well as imaging features regressed after four months, treated by cast immobilization followed by weight-bearing as tolerated (d).
history of Immunoglobulin A vasculitis (Henoch-Schönlein purpura) and Hashimoto thyroiditis. The mean age at presentation of symptoms was 11 years (8 to 14) and the mean follow-up was one year and one month (5 months to 2 years 1 month). All patients presented with unilateral symptoms.

**Clinical features and disease course**

In all children, no report of hip-or knee-related pathology was noted. Three children presented with a minor trauma prior to the symptoms necessitating consultation, consisting of an ankle sprain in one patient and an undisplaced metatarsal fracture at least three months prior to first presentation in two other patients, as detailed in Table 1. In all patients, the prior trauma was treated by another physician, before consulting a foot and ankle surgeon at our clinic.

The average duration of symptoms before the first visit was six months (1 to 15). Three patients presented with a history of pain solely during sports. The other three patients complained of pain during stance and walking, with one patient unable to support their weight on the affected limb at first presentation. Two patients presented with swelling, one with isolated swelling of the ankle and one with swelling of both the ankle and hindfoot. The patient with a history of inflammatory diseases showed no localized joint inflammation, thus no joint aspiration or rheumatological investigation was performed. There was no report of skin colour, temperature or texture changes, nor of muscle atrophy or allodynia. On clinical examination, two children showed decreased passive mobilization.

---

**Fig. 2** Sagittal turbo inversion recovery magnitude MR imaging sequences of an eight-year-old boy (case 2), performed for atraumatic pain in the sinus tarsi on weight-bearing initially (a and c). After seven months of restricted weight-bearing, the pain transferred to the first tarsometatarsal joint, correlating with diminished signal intensity in the talus and calcaneus, and the new appearance of marrow oedema at the proximal metatarsal area (b and d).
of the hindfoot. No clinical ankle instability was reported in these children. In four patients, the pain was localized to the sinus tarsi, in one patient at the navicular bone and in one patient at the lateral mid- and hindfoot (Table 1).

Relative rest and restricted weight-bearing as tolerated were advised to all patients. Two patients (cases 3 and 6) did not receive any additional treatment aids. Orthotic insoles were prescribed for two patients (cases 1 and 2). A weight-bearing short leg cast was used as a protective aid in three cases (cases 2, 4 and 5) for four weeks (Table 1).

The average time for initial symptoms to improve during treatment was six months (2 to 15). Two patients had recurrent symptoms after initial improvement (cases 1 and 4) (Fig. 1). Another patient (case 5) demonstrated a prolonged disease course with stagnation of pain. Only one patient (case 2) showed clear migration of clinical

### Table 2 Imaging features

| Case | 1 | 2 | 3 | 4 | 5 | 6 |
|------|---|---|---|---|---|---|
| Number of MRI scans | 3 | 3 | 2 | 5 | 5 | 2 |
| Location of initial marrow oedema | Talonavicular, posterior calcaneus | Talocalcanear, posterior calcaneus | Talus, navicular, posterior calcaneus | Talonavicular, calcaneocuboidal | Talonavicular, talus, calcaneus | Talonavicular, calcaneus |
| Number of tarsal bones affected | 7 | 8 | 4 | 4 | 8 | 6 |
| Joint effusion | None | None | Talonavicular | None | None | None |
| Time until initial improvement of imaging | 11 mths | 13 mths | 6 mths | 2 mths | 16 mths | None |
| Recurrence/migration | More prominent calcaneal oedema band 5 mths after diagnosis | Medial side of calcaneus and TMT1 joint more affected 7 mths after onset | None | Anterior calcaneal patch 10 mths after symptom onset, after regression of initial talonavicular oedema | More prominent patchy oedema in calcaneus appearing 5 mths after onset | None |
| Time until resolution of transient oedema | 11 mths | 13 mths | 6 mths | 14 mths | 16 mths | 5 mths |
| Residual oedema | Remaining punctiform islands of red marrow | Remaining punctiform islands of red marrow | None | None | None | None |

**Fig. 3** MR imaging on diagnosis of bone marrow oedema syndrome in a ten-year-old boy (case 6) with pain in the sinus tarsi area, showing characteristic findings of increased signal intensity on turbo inversion recovery magnitude (a), decreased on T1-w sequences (b) and slightly increased on T2 3D-double-echo steady state with water excitation-w sagittal sequences (c).

**Fig. 4** Nine-year-old girl (case 1) presenting initially with pain localized to the sinus tarsi area, with T2-w MR imaging showing patchy areas of increased signal intensity at the anterior talar body and bow-shaped at the midportion of the calcaneus (a). Follow-up MR imaging after seven months show regression of the patchy areas (b), with improvement of symptoms. This image also shows the remaining red bone marrow islands in an asymptomatic patient.

---

**Table 2** Imaging features

- **Case 1**: 3 MRI scans, pain localized to Talonavicular, posterior calcaneus, initial improvement at 11 mths, no recurrence, residual punctiform islands of red marrow.
- **Case 2**: 3 MRI scans, pain localized to Talocalcanear, posterior calcaneus, initial improvement at 13 mths, no recurrence, residual punctiform islands of red marrow.
- **Case 3**: 2 MRI scans, pain localized to Talus, navicular, posterior calcaneus, initial improvement at 6 mths, no recurrence, no residual oedema.
- **Case 4**: 5 MRI scans, pain localized to Talonavicular, calcaneocuboidal, initial improvement at 2 mths, no recurrence, no residual oedema.
- **Case 5**: 5 MRI scans, pain localized to Talonavicular, talus, calcaneus, initial improvement at 16 mths, no recurrence, no residual oedema.
- **Case 6**: 2 MRI scans, pain localized to Talonavicular, calcaneus, initial improvement at 5 mths, no recurrence, no residual oedema.
symptoms (Fig. 2). Mean duration of treatment was nine months (3 to 15). Eventually all children were able to return to their daily activity and premorbid sports level, with a complete resolution of all symptoms.

**Imaging features**

All imaging features are summarized in Table 2. All patients had at least two MRI scans, and two patients (case 4 and 5) had up to five. In all patients, MRI images showed the presence of patchy areas of increased signal intensity on T2-weighted and TIRM images, with a decreased signal intensity on T1-weighted sequences (Fig. 3). On average, six tarsal bones were involved (4 to 8). The main localization of these patches was in the talar neck and navicular bone (100%). A second important localization was the posterior portion of the calcaneus, observed in five children (83%), where in four of these patients a similar bow-shaped area of increased intensity was observed (Fig. 4). No apophyseal involvement in the calcaneus was reported. In two patients (cases 3 and 4) the presence of talonavicular joint fluid was observed. No patient showed any tendon or ligament injury or pathology, nor other imaging features associated with chronic ankle instability (such as anterolateral impingement signs, anterior talofibular ligament avulsions, peroneal injuries or synovitis, peroneal retinaculum pathology or talar osteochondral lesions).

In all patients, a concurrent amelioration of clinical symptoms with a regression of the patchy bone marrow oedema was observed. In multiple cases, persistent diffuse punctiform increase in signal intensity was found on MRI images, with regression of the patchy areas and absence of symptoms (Fig. 5).

**Control group**

In order to provide a control group, ten patients undergoing MRI imaging of the foot and ankle for different diagnoses were reviewed. This group comprised two male and eight female children, with a mean age of nine years (6 to 12). All clinical and imaging features of these cases are summarized in Table 3. None of these children had a significant medical history. Two children were diagnosed with Sever’s disease, another two children showed a sinus tarsi syndrome, based on planovalgus in one and repetitive hindfoot stress in the other child. Two cases were diagnosed with ankle instability, one child demonstrated a simple bone cyst in the calcaneus. One patient was diagnosed with ankle synovitis and a slow rehabilitation after arthroscopic treatment of an osteochondral lesion at the talar dome. Two children featured bilateral ankle MRI imaging, one being diagnosed with ankle instability on

![Fig. 5 Turbo inversion recovery magnitude sequencing sagittal images of the foot and ankle in an eight-year-old girl (case 5) presenting with pain on the lateral aspect of the mid- and hindfoot, unable to bear weight at initial diagnosis (a). One year and four months of intermittent treatment by casting eventually led to improvement of symptoms, with final imaging showing small punctiform asymptomatic increased signal intensity foci, suggesting residual islands of red bone marrow (b).](image1)

![Fig. 6 Sagittal turbo inversion recovery magnitude sequencing image of the foot and ankle in a 12-year-old girl (control group case 3) diagnosed with a sinus tarsi syndrome and cavovarus alignment after presenting with pain in the sinus tarsi area after walking. MRI imaging shows no pathological features and no patchy oedema in the tarsus.](image2)
one side, and an osteochondral talar lesion on the contralateral ankle. The other child had a bilateral symptomatic calcaneonavicular coalition. None of the MRI images in these cases showed the presence of patchy areas of increased signal intensity on T2-weighted and TIRM images (example in Fig. 6). One child of eight years old showed small punctiform increased signal intensity foci in the posterolateral talus and posterior calcaneum, suggesting physiological residual islands of red bone marrow with a clinical diagnosis of Sever’s disease.

Discussion

In this study we describe six paediatric patients with BMOS of the foot and ankle. The ages of the patients varied between eight and 14 years. To our knowledge, this is the first case series to be described in an exclusively skeletally immature population, where clinical data shows a similar course as imaging features.

Few articles have been published concerning TBMO in children. In 2002, Aigner et al reported a case of TBMO in the acetabulum of a 15-year-old girl, which was successfully treated by iloprost. MRI imaging showed a characteristic low-intensity signal in T1-weighted and an increased signal in T2-weighted sequences. Both sequences normalized three months after treatment. Kröger et al (2004) described the case of an eight-year-old boy suffering from TBME in both hands and feet. MRI imaging of both joints showed BMOS, yet radiographic examination showed marked osteopenia in the tarsal area, making the diagnosis of transient osteoporosis more likely. No biopsy was performed to confirm the diagnosis of osteoporosis, and a spontaneous improvement of symptoms was observed within three months. In 2010, Orr et al reported a case series of 14 juvenile and young adult patients with prolonged, atraumatic foot and ankle pain, showing characteristic imaging features on MRI. Follow-up MRI imaging was performed for four patients. Three patients showed an improvement in marrow intensity which could be correlated to their clinical improvement. One patient, who showed a prolonged symptom duration, had no improvement in MRI imaging. Two studies have suggested that the focal high intensity areas on T2 or STIR image sequences in foot and ankle MRI imaging in children could be physiological, due to residual red bone marrow. However, these imaging studies did not correlate the imaging data to the clinical data.

Reports of BMOS of the foot and ankle in adults often describe a unique localization of bone marrow oedema as well as more diffuse patterns of the affected bones. Most often and most prominently involved is the talus, which is also observed in our series. Typical findings of BMOS include migration of the oedema pattern and a recurrence of symptoms. The migratory character could be explained by recurring ischemic events in vessels. Migration of marrow oedema can occur within the tarsus, or to other joints often diagnosed with BMOS such as the hip or knee joint.

Table 3 Control group features

| Case | Sex | Age | Symptoms | Diagnosis | MRI features |
|------|-----|-----|----------|-----------|--------------|
| 1    | Female | 10 yrs 9 mths | Heel pain on exercise | Sever’s disease | No oedema, no pathological features |
| 2    | Female | 10 yrs 11 mths | Hindfoot pain during sports | Simple bone cyst in the calcaneus | Calcaneal simple bone cyst, slight oedema localized in the cuboid |
| 3    | Female | 12 yrs 2 mths | Sinus tarsi pain after walking | Sinus tarsi syndrome, cavovarus alignment | No oedema, no pathological features |
| 4 (bilateral) | Female | 6 yrs 4 mths | Posttraumatic medial ankle pain right, atraumatic chronic ankle pain left | Ankle instability right, left osteochondral lesion talat dome | Right: No oedema, no pathologic features; left: talar dome osteochondral lesion, no marrow oedema |
| 5    | Female | 8 yrs 11 mths | Chronic sinus tarsi pain after sprain | Ankle instability | No oedema, no pathological features |
| 6    | Male   | 7 yrs 10 mths | Repeated ankle sprains | Ankle instability, lateral synchondrosis | Slight oedema surrounding synchondrosis, no other oedema or pathological features |
| 7    | Female | 10 yrs 6 mths | Sinus tarsi pain during high level sports (dancing) | Planovalgus alignment, sinus tarsi syndrome with positive SPECT-CT talonavicular and subtalar | Slight oedema in the talar tail, no diffuse oedema or other pathological features |
| 8 (bilateral) | Female | 11 yrs 5 mths | Bilateral sinus tarsi pain during weight-bearing | Bilateral calcaneonavicular coalition | Right: calcaneonavicular coalition, no oedema; left: calcaneonavicular coalition, oedema at the distal fibular physis |
| 9    | Female | 12 yrs 3 mths | Ongoing ankle pain after arthroscopic treatment of talar osteochondral lesion | Synovitis and stiffness of the ankle joint | Osteochondral lesion in the talus with surrounding oedema, slight oedema in the talar tail, no diffuse oedema |
| 10   | Male   | 8 yrs | Heel pain during athletics | Sever’s disease | No diffuse patchy oedema, punctiform red marrow islands in talus and calcaneus |
our case series two children showed a migratory pattern of oedema within the tarsus, one of them after improvement of initial symptoms (case 4). In adult BMOS patients follow-up MRI imaging shows an overall improvement in T2-weighted sequence intensity corresponding to an amelioration of pain.\textsuperscript{15,18,25,39,43,44} Several studies have reported an (incomplete) resolution of marrow oedema after treatment but these studies made no connection to symptomatic findings.\textsuperscript{7,17,19,22,23,41} In 23% of BMOS patients a recurrence of symptoms can be seen when the foot and ankle are affected, often after an average time interval of eight months.\textsuperscript{2,11,13,14} Singh et al\textsuperscript{2} reported a recurrence rate of 44% within the ipsilateral foot with a mean follow-up of 15.6 months. In our patient group we had one patient (case 4) with recurrent BMOS symptoms at another site within the tarsal bones, returning eight months after symptom and oedema regression in T2-weighted MRI sequences. Another patient showed a prolonged disease course, with symptoms and MRI images taking up to 16 months to improve.

Three of our patients presented after a minor trauma several months before initial imaging. In a paediatric population minor trauma should be considered to be part of the daily life of playing children, and should not be expected to lead to such fulminant osseous reaction patterns. Some authors suggest TBMO to be one of several possible terms for a pathology also comprising algodystrophy or complex regional pain syndrome,\textsuperscript{3} however, none of our cases demonstrated typical clinical signs of algodystrophy, such as skin or vasomotor changes, or muscle atrophy. Common diagnoses to be ruled out at this age are Sever’s disease or ankle instability, of which none of our patients showed clinical or radiological findings.

The pathophysiology of BMOS remains discussed up until today. Risk factors of BMOS are chemo- or radiotherapy, corticosteroid therapy, alcohol or nicotine abuse, (micro)trauma, sickle cell anaemia, lipid metabolism disorders, rheumatic diseases or vitamin C deficiency.\textsuperscript{3,8,23,45} Several authors have shown a higher rate of bone turnover and vitamin D deficiency to be associated to BMOS.\textsuperscript{52,46} Screening of hypovitaminosis could be useful in BMOS patients, but this was not performed in our group.

All our patients received conservative treatment measures, comprised of rest and restricted weight-bearing. Orthotic insoles, full weight-bearing cast and a short leg walker boot were added to the treatment when necessary. No standard treatment protocol was implemented. Adult BMOS patients are often treated conservatively with physical therapy, nonsteroidal anti-inflammatory drugs and other immobilizing orthoses such as a stiff soled postoperative shoe.\textsuperscript{2,12,16} In literature, the use of iloprost, a vasoactive synthetic prostacycline analogue, has been shown to provide favourable results, with significant improvements in both function and pain scores, and a (partial) regression of marrow oedema signal on MRI.\textsuperscript{11,17,23,41,43} Iloprost causes a dilatation of arterioles and venules, decreasing capillary permeability and inhibiting thrombocyte aggregation.\textsuperscript{11,47} A single case report recorded the use of iloprost in a 15-year-old girl diagnosed with BMOS of the acetabulum, with pain in rest decreasing after three days of treatment, and without report of adverse effects.\textsuperscript{3} Iloprost has been proven to be safe and efficient in other indications for use in children, with observation of minor adverse effects such as headache and hypotension.\textsuperscript{48-52} However, as insufficient long-term data concerning the efficiency or safety of the product is available, the indication to use iloprost for a self-limiting transient condition such as BMOS seems questionable. Decompressive drilling of the bone has been described in the proximal femur.\textsuperscript{22,29} A single retrospective case series on drilling the calcaneus for chronic heel pain was published by Santini et al in 2003,\textsuperscript{53} showing moderate clinical results for this technique, performed for multiple diagnoses. This pathology shows diffuse involvement of multiple tarsal bones in our case series, and has a likely self-limiting disease course. Since an overall good response to conservative treatment measures, we believe surgery with its possible complications should be avoided in paediatric BMOS. We advise applying conservative treatment measures tailored to the patient and their symptoms, varying from relative rest in milder cases to non-weight baring casts when disabling pain is present. The main goal of treatment is to minimize pain symptoms while maintaining the patients’ functionality. Reassuring the patient and their parents of the self-limiting course of the disease is an important aspect.

We believe that connecting imaging data to clinical symptoms is necessary to provide a correct diagnosis, especially in children, and guide further diagnostic processes and treatment decisions. In our case series, we found a distinct pattern of patchy involvement in multiple locations of the foot, irrespective of the patient’s age, regressing in parallel with clinical symptoms. This is an important finding, since in earlier imaging studies in children, clinical data could often not be linked to MRI findings. We propose that once the diagnosis is confirmed, clinical symptoms should guide the further treatment.

We provided a control group, by reviewing a population of children of a corresponding age with clear underlying clinical and imaging-based diagnoses. None of these children showed the well-defined patchy area involvement of increased signal intensity on T2 and TIRM-weighted images, supporting our hypothesis.

There are several limitations to this study that must be taken into consideration. The first limitation is the small sample size and the follow-up being limited to the clinical course of each patient. All clinical information was retrieved from patient files and no objective measurement tools for pain and function improvement were
used. Several children were included after minor trauma, as stated above however, we do not believe such daily traumatisms in the life of a child could lead to a fulminating marrow oedema reaction. We do not exclude the fact that bone marrow oedema in the talus, calcaneus or navicular could be possible because of a contusional reaction, that can be sustained for several months and difficult to differentiate from a bone bruise. Differentiation between physiological, residual red bone marrow, altered weight-bearing patterns and pathological BMOS should be further studied by prospective, comparative studies in a paediatric population. We believe the strength of this case series is the clear parallel progression of clinical and MRI data over the whole course of the disease.

**Conclusion**

In this case series both clinical and MRI data of six paediatric patients with BMOS of the foot and ankle is reported. As BMOS is transient and likely self-limiting, we believe no pharmacological treatment is warranted, and conservative treatment measures should be implemented to improve patient comfort during the disease course. The clinical progression of symptoms shows a parallel course to the MRI findings, making consecutive follow-up MRI imaging unnecessary. A swift and correct diagnosis of BMOS, based on clinical findings and bone marrow oedema patterns on MRI with no definite underlying causes, could prevent unnecessary diagnostic investigations and invasive treatments for patients.

Received 16 December 2019; accepted after revision 12 July 2020.

**COMPLIANCE WITH ETHICAL STANDARDS**

**FUNDING STATEMENT**

No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

**OA LICENCE TEXT**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.

**ETHICAL STATEMENT**

Ethical approval: The authors declare that they have no conflict of interest and received no specific funding for this study. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent: Informed consent was not required due to the retrospective nature of this work.

**ICMJE CONFLICT OF INTEREST STATEMENT**

None declared.

**AUTHOR CONTRIBUTIONS**

HDH: Conception and design of study, Acquisition of data, Analysis and/or interpretation of data, Drafting the manuscript, Approval of the version of the manuscript to be published.

NVB: Conception and design of study, Revising the manuscript critically for important intellectual content, Approval of the version of the manuscript to be published.

SP: Revising the manuscript critically for important intellectual content, Approval of the version of the manuscript to be published.

AVR: Conception and design of study, Revising the manuscript critically for important intellectual content, Approval of the version of the manuscript to be published.

JDR: Analysis and/or interpretation of data, Approval of the version of the manuscript to be published.

SV: Conception and design of study, Analysis and/or interpretation of data, Revising the manuscript critically for important intellectual content, Approval of the version of the manuscript to be published.

**REFERENCES**

1. Hofmann S, Kramer J, Vakil-Adli A, Aigner N, Breitenseher M. Painful bone marrow edema of the knee: differential diagnosis and therapeutic concepts. Orthop Clin North Am 2004;35:321-333, ix.

2. Singh D, Ferrero A, Rose B, Goldberg A, Cullen N. Bone marrow edema syndrome of the foot and ankle: mid- to long-term follow-up in 18 patients. Foot Ankle Spec 2016;9:218-226.

3. Mirghasemi SA, Trepman E, Sadeghi MS, Rahimi N, Rashidinia S. Bone marrow edema syndrome in the foot and ankle. Foot Ankle Int 2016;37:1364-1373.

4. Korompilias AV, Karantanas AH, Lykissas MG, Beris AE. Bone marrow edema syndrome. Skeletal Radiol 2009;38:425-436.

5. Patel S. Primary bone marrow edema syndromes. Rheumatology (Oxford) 2014;53:785-792.

6. Starr AM, Wessely MA, Albastaki U, Pierre-Jerome C, Kettner NW. Bone marrow edema: pathophysiology, differential diagnosis, and imaging. Acta Radiol 2008;49:771-786.

7. Bartl C, Imhoff A, Bartl R. Treatment of bone marrow edema syndrome with intravenous ibandronate. Arch Orthop Trauma Surg 2012;132:1781-1788.

8. Gigena LM, Chung CB, Lektrakul N, et al. Transient bone marrow edema of the talus: MR imaging findings in five patients. Skeletal Radiol 2002;31:262-267.

9. Hörterer H, Baumbach SF, Gregersen J, et al. Treatment of bone marrow edema of the foot and ankle with the prostacyclin analog iloprost. Foot Ankle Int 2018;39:1183-1191.

10. Froberg PK, Braunstein EM, Buckwalter KA. Osteonecrosis, transient osteoporosis, and transient bone marrow edema: current concepts. Radiol Clin North Am 1996;34:273-291.

11. Aigner N, Radda C, Meizer R, et al. Bone marrow edema in the foot - MRI findings after conservative therapy. Foot Ankle Surg 2005;11:87-91.

12. Fernandez-Canton G, Casado O, Capelastegui A, et al. Bone marrow edema syndrome of the foot: one year follow-up with MR imaging. Skeletal Radiol 2003;32:273-278.
13. Lakanpal S, Ginsburg WW, Luthra HS, Hunder GG. Transient regional osteoporosis. A study of 56 cases and review of the literature. Ann Intern Med 1987;106:444-450.

14. Sprinchnorn AE, O’Sullivan R, Beischer AD. Transient bone marrow edema of the foot and ankle and its association with reduced systemic bone mineral density. Foot Ankle Int 2011;32:S508-S512.

15. Limaye R, Tripathy SK, Pathare S, Saeed K. Idiopathic transient osteoporosis of the talus: a cause for unexplained foot and ankle pain. J Foot Ankle Surg 2012;51:632-635.

16. Orr JD, Sabesan V, Major N, Nunley J. Painful bone marrow edema syndrome of the foot and ankle. Foot Ankle Int 2010;31:949-953.

17. Disch AC, Matziolis G, Perka C. The management of necrosis-associated and idiopathic bone-marrow oedema of the proximal femur by intravenous iloprost. J Bone Joint Surg Br 2005;87-B:560-564.

18. Arazi M, Yel M, Uguz B, Emlik D. Be aware of bone marrow edema syndrome in ankle arthroscopy: a case successfully treated with iloprost. Arthroscopy 2006;22:909.

19. Mayerhoefer ME, Kramer J, Breitenseher MJ, et al. Short-term outcome of painful bone marrow oedema of the knee following oral treatment with iloprost or tramadol: results of an exploratory phase II study of 41 patients. Rheumatology (Oxford) 2007;46:1460-1465.

20. Meizer R, Meraner D, Meizer E, et al. Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost. Indian J Orthop 2009;43:36-39.

21. Jäger M, Zilkens C, Bittersohl B, et al. Efficiency of iloprost treatment for osseous malperfusion. Int Orthop 2011;35:761-765.

22. Beckmann J, Schmidt T, Schaumburger J, et al. Infusion, core decompression, or infusion following core decompression in the treatment of bone edema syndrome and early avascular osteonecrosis of the femoral head. Rheumatol Int 2013;33:1561-1565.

23. Röhrner E, Zippelius T, Steindl D, Fussi J, Perka C. Effects of intravenous iloprost therapy in patients with bone marrow oedema of the foot and ankle. Eur J Orthop Surg Traumatol 2014;24:1669-1676.

24. Ringe JD, Dorst A, Faber H. Effective and rapid treatment of painful localized transient osteoporosis (bone marrow edema) with intravenous ibandronate. Osteoporos Int 2005;16:2063-2068.

25. Emad Y, Ragab Y, El-Shaarawy N, Rasker JJ. Transient osteoporosis of the hip, complete resolution after treatment with alendronate as observed by MRI description of eight cases and review of the literature. Clin Rheumatol 2012;31:1641-1647.

26. Baier C, Schaumburger J, Götz J, et al. Bisphosphonates or prostacyclin in the treatment of bone-marrow oedema syndrome of the knee and foot. Rheumatol Int 2013;33:1397-1402.

27. Simon MJK, Barvencik F, Luttke M, et al. Intravenous bisphosphonates and vitamin D in the treatment of bone marrow oedema in professional athletes. Injury 2014;45:981-987.

28. Rolvien T, Schmidt T, Butschmidt S, Amling M, Barvencik F. Denosumab is effective in the treatment of bone marrow oedema syndrome. Injury 2017;48:874-879.

29. Zippelius T, Strube P, Matziolis G, et al. Cone beam-navigated core decompression of bone marrow edema syndrome. Arch Orthop Trauma Surg 2020 Jan 20. (Epub ahead of print)

30. Pay NT, Singer WS, Bartal E. Hip pain in three children accompanied by transient abnormal findings on MR images. Radiology 1989;171:147-149.

31. Aigner N, Petje G, Schneider W, et al. Juvenile bone-marrow oedema of the acetabulum treated by iloprost. J Bone Joint Surg (Br) 2002;84-B:1050-1052.

32. Kröger L, Arikoski P, Komulainen J, Seuri R, Kröger H. Transient bone marrow oedema in a child. Ann Rheum Dis 2004;63:1528-1529.

33. Joshi V, Hermann G, Balwani M, Simpson WL. Painless transient bone marrow edema syndrome in a pediatric patient. Skeletal Radiol 2014;43:1605-1619.

34. Pal CR, Tasker AD, Ostlere SJ, Watson MS. Heterogeneous signal in bone marrow on MRI of children’s feet: a normal finding? Skeletal Radiol 1999;28:274-278.

35. Iyer RS, Thapa MM. MR imaging of the paediatric foot and ankle. Pediatr Radiol 2013;43:507-519.

36. Chan BY, Gill KG, Rebsamen SL, Nguyen JC. MR Imaging of Pediatric Bone Marrow. Radiographics 2016;36:1911-1930.

37. Shabshin N, Schweitzer ME, Morrison WB, et al. High-signal 12 changes of the bone marrow of the foot and ankle in children: red marrow or traumatic changes? Pediatr Radiol 2006;36:670-676.

38. Kirby AB, Beall DP, Murphy MP, Ly JQ, Fish JR. Magnetic resonance imaging findings of chronic lateral ankle instability. Curr Probl Diagn Radiol 2005;34:196-203.

39. Calvo E, Alvarez L, Fernandez-Yruegas D, Vallejo C. Transient osteoporosis of the foot. Bone marrow edema in 4 cases studied with MRI. Acta Orthop Scand 1997;68:577-580.

40. Radke S, Vispo-Seara J, Walther M, Ettl V, Eulert J. Transient bone marrow oedema of the foot. Int Orthop 2000;24:263-267.

41. Aigner N, Meizer R, Stolz G, et al. Iloprost for the treatment of bone marrow edema in the hindfoot. Foot Ankle Clin 2003;8:683-693.

42. Horas K, Fraissler L, Maier G, et al. High prevalence of vitamin D deficiency in patients with bone marrow edema syndrome of the foot and ankle. Foot Ankle Int 2017;38:760-766.

43. Aigner N, Petje G, Steinboeck G, et al. Treatment of bone-marrow oedema of the talus with the prostacyclin analogue iloprost. An MRI-controlled investigation of a new method. J Bone Joint Surg (Br) 2001;83-B:853-858.

44. Berger CE, Kröner AH, Kristen KH, et al. Transient bone marrow edema syndrome of the knee: clinical and magnetic resonance imaging results at 5 years after core decompression. Arthroscopy 2006;22:866-871.

45. Rodriguez S, Paniagua O, Nugent KM, Phy MP. Regional transient osteoporosis of the foot and vitamin C deficiency. Clin Rheumatol 2007;26:976-978.

46. Oehler N, Mussawy H, Schmidt T, Rolvien T, Barvencik F. Identification of vitamin D and other bone metabolism parameters as risk factors for primary bone marrow oedema syndrome. BMC Musculoskelet Disord 2018;19:451.

47. Grant SM, Goa KL. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 1992;43:889-924.
48. Li Q, Dimopoulos K, Zhang C, et al. Acute effect of inhaled iloprost in children with pulmonary arterial hypertension associated with simple congenital heart defects. Pediatr Cardiol 2018;39:757-762.

49. Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004;43:229-233.

50. Cekic S, Kilic SS. Iloprost treatment in pediatric patients with complicated Raynaud’s phenomenon. Lupus 2016;25:558-560.

51. Lackner H, Benesch M, Moser A, et al. Aseptic osteonecrosis in children and adolescents treated for hemato-oncologic diseases: a 13-year longitudinal observational study. J Pediatr Hematol Oncol 2005;27:259-263.

52. Jäger M, Zilkens C, Westhoff B, et al. Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childhood cancer. Anticancer Res 2009;29:3439-3440.

53. Santini S, Rebeccato A, Schiavon R, Nogarin L. Percutaneous drilling for chronic heel pain. J Foot Ankle Surg 2003;42:296-301.